Valuation: Xencor, Inc.

Market Cap 182.39Cr 157.99Cr 149.39Cr 135.25Cr 253.84Cr 17TCr 255.75Cr 1.78TCr 685.87Cr 8.87TCr 685.11Cr 669.91Cr 28TCr P/E 2026 *
-7.98x
P/E 2027 * -7.59x
Enterprise Value 139.09Cr 120.48Cr 113.92Cr 103.14Cr 193.57Cr 13TCr 195.03Cr 1.36TCr 523.04Cr 6.77TCr 522.46Cr 510.87Cr 22TCr EV / Sales 2026 *
9.71x
EV / Sales 2027 * 14.6x
Free-Float
98.78%
Yield 2026 *
-
Yield 2027 * -
1 day-3.53%
1 week-6.26%
Current month-12.91%
1 month+2.70%
3 months+94.47%
6 months+97.38%
Current year+55.09%
1 week 23.45
Extreme 23.4501
26.18
1 month 22.79
Extreme 22.79
30.61
Current year 10.38
Extreme 10.375
30.61
1 year 8.49
Extreme 8.49
30.61
3 years 6.92
Extreme 6.92
30.61
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 01/02/2005
Director of Finance/CFO 48 09/04/2024
Chief Tech/Sci/R&D Officer 61 01/10/2006
Director TitleAgeSince
Director/Board Member 55 01/08/1997
Director/Board Member 58 25/07/2014
Director/Board Member 72 18/03/2015
Date Insider Type Main position Quantity % Market Cap. Importance
16/06/26 Free

Director

30,906 0.0417%
10/04/26 Sell

Chief Financial Officer

3,499 0.0048%
05/03/26 Sell

Chief Technology Officer

6,620 0.0090%
Change 5-day change 1-year change 3-year change Capi.($)
-3.53%-6.26%+179.68%+14.77% 182.39Cr
-1.38%+2.23%+48.54%+100.96% 7.02TCr
-1.04%-0.81%+34.61%+75.16% 6.26TCr
-4.70%-3.92%-16.17%+350.92% 2.74TCr
+0.16%+1.53%+34.92%+17.47% 2.57TCr
-1.53%-1.10%-0.32%-13.70% 2.48TCr
+1.61%-0.69%+20.85%-19.42% 1.95TCr
+1.26%-9.06%+165.21%+308.08% 1.55TCr
-3.91%-5.71%-8.71%+521.92% 1.47TCr
-6.79%-0.41%-9.13%+820.32% 1.47TCr
Average -1.97%-1.98%+44.95%+217.65% 2.77TCr
Weighted average by Cap. -1.56%-0.69%+32.71%+164.78%

Financials

2026 *2027 *
Net sales 14Cr 12Cr 12Cr 11Cr 20Cr 1.37TCr 20Cr 139.99Cr 54Cr 696.61Cr 54Cr 53Cr 2.22TCr 12Cr 11Cr 10Cr 9.25Cr 17Cr 1.2TCr 17Cr 121.91Cr 47Cr 606.64Cr 47Cr 46Cr 1.93TCr
Net income -24Cr -21Cr -20Cr -18Cr -33Cr -2.3TCr -34Cr -234.34Cr -90Cr -1.17TCr -90Cr -88Cr -3.72TCr -28Cr -25Cr -23Cr -21Cr -40Cr -2.73TCr -40Cr -278.07Cr -106.98Cr -1.38TCr -106.86Cr -104.49Cr -4.41TCr
Net Debt -43Cr -38Cr -35Cr -32Cr -60Cr -4.15TCr -61Cr -423.23Cr -162.83Cr -2.11TCr -162.65Cr -159.04Cr -6.72TCr -
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
15/26/15 $23.73 -3.28% 4,75,934
14/26/14 $24.53 +0.49% 8,58,322
11/26/11 $24.41 +0.62% 9,05,274
10/26/10 $24.26 -2.73% 13,60,986
09/26/09 $24.94 -1.54% 11,78,304
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
24.53USD
Average target price
30.75USD
Spread / Average Target
+25.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XNCR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!